Neoprobe Corporation (OTC BB: NEOP) has focused their efforts on developing and commercializing novel biomedical products that address the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. The company’s main area of dedication is on improving cancer surgery outcomes by utilizing their market-leading gamma detection devices in conjunction with radiopharmaceutical agents.
NeoGenomics, Inc. (OTC BB: NGNM) is known as the only publicly-traded pure-play laboratory testing service provider that has a specific focus on high revenue cancer genetics testing. The combination of advances in technology and genetic research, with the complete sequencing of the human genome, sophisticated new scientific testing tools to diagnose and treat diseases have been made possible. The company’s two facilities in Ft. Myers, Fla., and other facilities in Nashville, Tenn. and Irvine, Calif provide state of the art genetic testing. For further information, visit the Company's web site at www.neogenomics.org.
Aradigm Corporation (OTC BB: ARDM), an emerging specialty pharmaceutical company, is committed to developing and commercializing a portfolio of drugs designed to treat severe respiratory diseases. With its clinical expertise, targeted development efforts, and strength of a well accomplished leadership team, the company is poised to capitalize on niche opportunities for new and improved products used in the treatment of severe respiratory disease. For further information, visit the Company's web site at www.aradigm.com.
NAPCO Security Systems, Inc. (NASDAQ:NSSC) is a leading manufacturer of a wide array of security products, developing advanced technologies for intrusion, fire, video, wireless, access control and door locking systems. With headquarters in New York, the company has branched into the international market by opening offices in the United Kingdom, the Caribbean, and Dubai. While many of NAPCO’s products have gained national attention, their Alarm Lock Division is the company’s fastest growing product and has been a leader in the marketplace since 1987. For further info, visit the company website at: www.napcosecurity.com.
Antigenics, Inc. (NASDAQ: AGEN) is focused on enhancing and extending the lives of patients by developing superior health care products for a broad array of cancers, infectious diseases and autoimmune disorders. Earlier this year, the company’s patient-specific cancer vaccine Oncophage ® (vitespen) was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. Antigenics is now committed to exploring other major geographical territories for regulatory approval of Oncophage. For further information, visit the Company's web site at www.antigenics.com.
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS), a clinical-stage biopharmaceutical company, is focused on improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing two potentially complementary agents for the treatment of chronic hepatitis C: ANA598, a non-nucleoside polymerase inhibitor; and ANA773, an oral TLR7 agonist prodrug. For further information, visit the Company's web site at www.anadyspharma.com.
Nanogen, Inc. (NASDAQ: NGEN) is focused on developing diagnostic products that provide enhanced patient care. The company’s products are designed to offer faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These superior products include molecular diagnostic kits and reagents, as well as rapid test kits that can be utilized in urgent care settings or at the point-of-care. Nanogen is committed to bringing better results to diagnostics and healthcare. For further information, visit the Company's web site at www.nanogen.com.
Amerigo Resources Ltd. (TSX: ARG CN), through its wholly owned subsidiary, Minera Valle Central (MVC), focuses on producing copper and molybdenum concentrates. This subsidiary is treating all the fresh tailings from El Teniente's present production and has the right to treat the higher grade tailings from a 200 million tonne in situ tailings impoundment. Amerigo aims to increase production on an annualized basis to approximately 60 million pounds of copper and 1 million pounds of molybdenum. For further information, visit the Company's web site at www.amerigoresources.com.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company's web site at www.momentapharma.com.
American Tony Pharmaceutical, Inc. (OTC BB: AIMR), a manufacturer and distributor of pharmaceuticals and health care products in China, is focused on developing, manufacturing and marketing pharmaceutical and health care products through its wholly owned subsidiary, Harbin Tianmu Pharmaceutical Co., Ltd. ("Tianmu Pharmaceutical"). Founded in 1999 in Harbin, China, Tianmu Pharmaceutical operates all of its business activities in the People's Republic of China.
